Method for diagnosing diseases based on levels of anti-glycan antibodies
AssigneeGlycominds Ltd.
InventorsNir Dotan, Avinoam Dukler
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.
Claims54
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from a subject with digestive symptoms of Crohn's disease;
- detecting a level of an IgA anti-GlcNAc (β 1-4) GlcNAc (β) antibody (ACCA) in said sample by binding of said IgA ACCA in said sample to a carbohydrate reagent comprising an isolated GlcNAc (β 1-4) GlcNAc (β) glycan;
- and
- diagnosing Crohn's Disease in said subject by detection of an elevated level of said IgA ACCA in said test sample relative to a control reference level.
A method of diagnosing Crohn's disease in a subject, the method comprising
- providing a test sample from a subject with digestive symptoms of Crohn's disease;
- detecting a level of an anti-Glc (β 1-3) Glc (β) antibody (ALCA) in said sample by binding of said ALCA in said sample to a carbohydrate reagent comprising an isolated Glc (β 1-3) Glc (β) glycan;
- and
- diagnosing Crohn's Disease in said subject by detection of an elevated level of said antibody in said test sample relative to a control reference level.
A method of differentially diagnosing Crohn's disease or inflammatory bowel disease in a subject with digestive symptoms of Crohn's disease or inflammatory bowel disease, the method comprising
- providing a test sample from the subject;
- detecting a level of an anti-neutrophil cytoplasmic antibody (ANCA) in said sample;
- detecting a level of an IgG anti-Glc (β 1-3) Glc (β) antibody (ALCA) in said sample by binding of said ALCA in said sample to a carbohydrate reagent comprising an isolated Glc (β 1-3) Glc (β) glycan;
- the method further comprising identifying a specific anti-Mannan antibody (ASCA) selected from the group consisting of
- IgG ASCA and
- IgA ASCA,
- wherein absence of ANCA and presence of at least one of said IgG ALCA IgG ASCA, or IgA ASCA antibodies in said test sample indicates the subject has Crohn's disease, and
- wherein the subject is assessed as having inflammatory bowel disease if ANCA is present and at least one of said IgG ALCA, IgC ASCA, IgA ASCA antibodies are present in said test sample.
A method of diagnosing Crohn's disease in a subject, the method comprising providing a test sample from a subject with digestive symptoms of Crohn's disease;
- detecting a level of an anti-GlcNAc (β 1-4) GlcNAc (β) antibody (ACCA) in said sample by binding of said ACCA in said sample to an isolated GlcNAc (β 1-4) GlcNAc (β) on a solid phase;
- detecting a level of an anti-Glc (β 1-3) Glc (β) antibody (ALCA) in said sample by binding of said ALCA in said sample to an isolated Glc (β 1-3) Glc (β) on a solid phase;
- detecting a level of an anti-mannan antibody (ASCA) in said sample by binding of said ASCA in said sample to an isolated mannan on a solid phase;
- and
- detecting a level of an anti-Man(α1,3)Man(α) antibody (AMCA) in said sample by binding of said AMCA in said sample to an isolated Man(α1,3)Man(α) on a solid phase;
- wherein elevated levels of at least two of said antibodies in said test sample relative to control reference levels indicate the subject has Crohn's disease.
Dependencies are inferred from the claim text.